Followers | 199 |
Posts | 21896 |
Boards Moderated | 2 |
Alias Born | 11/07/2005 |
Monday, April 03, 2006 10:17:20 AM
http://www.theasianinvestor.com/reports/tedg.htm
VALUATION RATING
Reflecting the size of TianYuan Bio-pharmaceutical research facilities and extensive background in vaccine research, we feel it to be 'fair' to give TEDG a target market cap value of $100 million as compared to other bird flu vaccine producers trading today. With 82 million shares currently issued and outstanding, this would give TEDG a short-term price valuation target of around $1.20 a share. Investors should also be advised that many questions still remain on the potential merger and should exercise moderate caution until audited financials can be made available. Thus, Ludlow Capital is currently withholding a rating on TEDG until additional research information can be made available to the general public.
FEATURED Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM
North Bay Resources Announces Mt. Vernon Gold Mine Bulk Sample, Sierra County, California • NBRI • Sep 11, 2024 9:15 AM
One World Products Issues Shareholder Update Letter • OWPC • Sep 11, 2024 7:27 AM
Kona Gold Beverage Inc. Reports $1.225 Million in Revenue and $133,000 Net Profit for the Quarter • KGKG • Sep 10, 2024 1:30 PM